We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The Alathur facility specializes in the production of Cephalosporin antibiotics
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This rating reflects Lupin's leadership in environmental transparency and performance
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Offers affordable, high-quality solutions for diabetes care
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
